Item 7.01 Regulation FD Disclosure.

On Monday, December 6, 2021, Biostage, Inc., or the Company, released an updated version of its investor presentation, which the Company may use from time to time. Among highlights on the business, operations, plans and outlook, the investor presentation provides details on possible clinical trial design. Investors should read the updated investor presentation in its entirety, including the cautionary statement regarding forward looking statements in the beginning of the investor presentation. The updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This Form 8-k and the investor presentation contain remarks regarding management's intentions, hopes, beliefs, expectations, or predictions of the future. These are forward looking statements that involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or in the Company's other periodic reports filed by the Company with the Securities and Exchange Commission. These documents are available in the Investors section of the Company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. The forward-looking statements in this Form 8-k and in the investor presentation speak only as of the date of the respective disclosure. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

The information disclosed under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit
Number     Title
  99.1       Investor Presentation
104        Cover Page Interactive Data File (formatted as Inline XBRL and contained
           in Exhibit 101)

© Edgar Online, source Glimpses